Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Schering-Plough,Pegylated liposomal doxorubicin,Advanced epithelial ovarian cancer (3rd-line treatment) - platinum resistant,Pegylated liposomal doxorubicin (Caelyx),Recommended for decline,Community and Hospital,Oncology Agents and Immunosuppressants
